Dallas, TXNCT03872102Now EnrollingIRB Ready

Parkinson Disease Clinical Trial in Dallas, TX

Access cutting-edge parkinson disease treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by University of Texas Southwestern Medical Center

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access parkinson disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related parkinson disease treatment provided free

Apply for This Dallas Location

Check if you qualify for this parkinson disease clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Parkinson Disease Study in Dallas

The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.

Sponsor: University of Texas Southwestern Medical Center

Who Can Participate

Inclusion Criteria

Diagnosis of Parkinson disease
Existence of sufficient clinical data from previous UTS Southwestern longitudinal study to determine progression rate (categorized as fast or slow)
Availability of suitable matched participant in the alternate progression group (fast or slow)
Willingness to participate in the imaging studies required for this study and to provide written informed consent For Aim 2: PD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for PD.
Duration of PD (since diagnosis) is \< 5 years
Willing to participate in imaging and clinical scoring visits, and provide written informed consent
Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move) MSA subjects will be recruited in accordance with the Second Consensus Statement on Diagnosis of Multiple System Atrophy.
Duration of MSA (since diagnosis) is \< 5 years
Willing to participate in imaging and clinical scoring visits, and provide written informed consent
Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study) PSP subjects will be recruited in accordance with the MDS Criteria for Diagnosis of Progressive Supranuclear Palsy and must meet the designation of "probable PSP" for inclusion.
Willing to participate in imaging and clinical scoring visits, and provide written informed consent
Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study) Control subjects will be recruited who meet the following criteria:
Roughly age and sex matched with the subjects in the PD cohort
No history or examination findings suggestive of any neurodegenerative disease
Normal gait, balance, and eye movements for age
No clinical evidence for symptomatic orthostatic hypotension
Willing to participate in imaging and clinical scoring visits, and provide written informed consent
Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)

Exclusion Criteria

For Aims 1 and 2:
Any contraindications to undergoing the multimodal imaging program
All females of child-bearing potential, between the ages of 18-55, will be excluded from the study, unless they are confirmed to be not pregnant with a pregnancy test prior to scanning
This study will require constant clear communication throughout the duration of the study; therefore, non-English speakers will be excluded
Right-handed finger amputees
Cast on right hand or fingers at the time of enrollment
Has clinically significant liver, kidney, lung, metabolic or hormone disturbances which pose safety risk
Has a current clinically significant heart disease that poses a safety risk
Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk
Has a history of relevant severe drug allergy or hypersensitivity
Have a history of drug, alcohol, or substance dependence or abuse within the last year, or prior prolonged history of dependence or abuse
Currently undergoing chemotherapy or radiation for cancer
Recreational drug use in past six months
Central nervous systems disease or brain injury that would preclude participation in this study
Psychiatric or neurological disorder that would preclude participation in this study
Inability to keep or maintain research appointments For Aim 1:
Severe disease progression such that participation in the imaging tests would be impossible or difficult
Non-availability of a suitable matched participant in the alternate progression group (fast or slow) For Aim 2: PD subjects
Unequivocal cerebellar abnormalities
Downward vertical gaze limitation or slowing of downward saccades
Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia
Parkinsonian features restricted to the lower limbs for \> 3 years
Treatment with dopamine blockers or depleters in a time course consistent with drug induced parkinsonism
Absence of an observable response to high dose levodopa despite moderate disease severity
Expert considers a diagnosis of alternative syndrome more likely than PD
Rapid progression of gait impairment requiring wheelchair within 5 years of onset
Complete absence of progression of motor symptoms over 5 years unless due to treatment
Early bulbar dysfunction within the first 5 years since diagnosis
Inspiratory respiratory dysfunction (stridor or frequent sighs)
Severe autonomic failure in the first 5 years
Recurrent falls (\>1 per year) because of impaired balance in the first 3 years
Disproportionate dystonic anterocollis or hand contractures of hands or feet within 10 years
Absence of any of the common non-motor features of PD despite 5 years of disease
Otherwise unexplained pyramidal tract signs (weakness, hyperreflexia, or extensor toe signs)
Bilateral symmetric parkinsonism MSA subjects
Clinically significant neuropathy
Hallucinations not induced by drugs
Onset after age 75 years
Family history of ataxia or parkinsonism
White matter lesions suggesting multiple sclerosis PSP subjects
Predominant, otherwise unexplained impairment of episodic memory, suggestive of AD (Alzheimer's disease)
Predominant, otherwise unexplained autonomic failure, e.g., orthostatic hypotension (orthostatic reduction in blood pressure after 3 minutes standing \> 30 mm Hg systolic or \> 15 mm Hg diastolic), suggestive of multiple system atrophy or Lewy body disease
Predominant, otherwise unexplained visual hallucinations or fluctuations in alertness, suggestive of dementia with Lewy bodies
Predominant, otherwise unexplained multisegmental upper and lower motor neuron signs, suggestive of motor neuron disease (pure upper motor neuron signs are not an exclusion criterion)
Sudden onset or step-wise or rapid progression of symptoms, in conjunction with corresponding imaging or laboratory findings, suggestive of vascular etiology, autoimmune encephalitis, metabolic encephalopathies, or prion disease
History of encephalitis
Prominent appendicular ataxia
Identifiable cause of postural instability, e.g., primary sensory deficit, vestibular dysfunction, severe spasticity, or lower motor neuron syndrome Control subjects a. In the investigator's opinion, an unsuitable candidate to serve as a control

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT03872102) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Parkinson Disease Treatment Options in Dallas, TX

If you're searching for parkinson disease treatment options in Dallas, TX, this clinical trial (NCT03872102) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced parkinson disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all parkinson disease clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Dallas, TX

See all parkinsons disease clinical trials recruiting in Dallas — not just this study.

Browse Parkinsons Disease Trials in Dallas →

Browse More Trials by Condition

Parkinsons Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX